Morgan Stanley upgraded Bausch + Lomb from Equal-Weight to Overweight and set a new price target of $21.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/5/2026 | $18.00 | Outperform → In-line | Evercore ISI |
| 12/11/2025 | $20.00 | Neutral → Buy | Citigroup |
| 12/2/2025 | $21.00 | Equal-Weight → Overweight | Morgan Stanley |
| 10/1/2025 | $16.00 | Neutral | Goldman |
| 5/2/2025 | $20.00 → $15.00 | Buy | H.C. Wainwright |
| 3/28/2025 | $24.00 → $15.00 | Overweight → Equal Weight | Wells Fargo |
| 12/11/2024 | $24.00 → $22.00 | Buy → Neutral | Citigroup |
| 12/2/2024 | $19.00 | Overweight → Equal-Weight | Morgan Stanley |
4 - Bausch & Lomb Corp (0001860742) (Issuer)
4 - Bausch & Lomb Corp (0001860742) (Issuer)
4 - Bausch & Lomb Corp (0001860742) (Issuer)
10-K - Bausch & Lomb Corp (0001860742) (Filer)
8-K - Bausch & Lomb Corp (0001860742) (Filer)
8-K - Bausch & Lomb Corp (0001860742) (Filer)
4 - Bausch & Lomb Corp (0001860742) (Issuer)
4 - Bausch & Lomb Corp (0001860742) (Issuer)
4 - Bausch & Lomb Corp (0001860742) (Issuer)
Evercore ISI downgraded Bausch + Lomb from Outperform to In-line and set a new price target of $18.00
Citigroup upgraded Bausch + Lomb from Neutral to Buy and set a new price target of $20.00
Morgan Stanley upgraded Bausch + Lomb from Equal-Weight to Overweight and set a new price target of $21.00
Global review highlights increasing prevalence of noninfectious ocular redness due to digital eye strain, dry eye disease, allergies and environmental exposures LUMIFY redness reliever eye drops (brimonidine tartrate 0.025%) are highlighted as a differentiated OTC option due to its highly selective α2 mechanism, with no tachyphylaxis over 29 days and virtually no rebound redness Review also notes a preservative-free formulation of brimonidine tartrate 0.025% showing comparable efficacy, safety and tolerability; Bausch + Lomb introduced LUMIFY Preservative Free Eye Drops in 2025 Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping peop
Delivered meaningful EBITDA margin expansion and operating leverage in the fourth quarter Fourth-Quarter 2025 Financial Results Revenue of $1.405 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $58 Million Adjusted EBITDA (non-GAAP)1 of $326 Million; Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP)1 of $330 Million Revenue Grew 10% as Reported and 7% on a Constant Currency1 Basis Compared to the Fourth Quarter of 2024 Full-Year 2025 Financial Results Revenue of $5.101 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $360 Million Adjusted EBITDA (non-GAAP)1 of $858 Million; Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP)1
Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its fourth-quarter and full-year 2025 financial results on Wednesday, Feb. 18, 2026. The company will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call. Conference Call Details Date: Wednesday, Feb. 18, 2026 Time: 8:00 a.m. ET Webcast: https://www.webcaster5.com/Webcast/Page/2883/53392 Pa
Bausch + Lomb Corporation (NYSE/TSX:BLCO) ("Bausch + Lomb" or the "Company"), a leading global eye health company dedicated to helping people see better to live better, today announced the election of the 10 directors nominated at its 2025 Annual Meeting of Shareholders (the "Annual Meeting") held on May 21, 2025. Detailed results of the vote follow: Name For Against Broker Non-Votes Nathalie Bernier 337,617,248 1,924,336 8,383,437 Gary Hu 337,591,706 1,949,878 8,383,437 Brett Icahn 337,474,287 2,067,297 8,383,437 Sarah B. Kavanagh 337,602,211 1,939,373
Richard De Schutter to Retire from Board Following 2024 Annual Meeting Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Karen L. Ling has been appointed to its Board of Directors (the "Board"), effective immediately. Current director Richard De Schutter will retire from the Board effective as of the company's 2024 Annual Meeting of Shareholders (the "Annual Meeting"). With Ms. Ling's appointment, the Board has been temporarily expanded to 11 members and is expected to revert to 10 directors following the Annual Meeting. "Since my return to the company, Richard has been a trusted advisor,
Papa will lead Emergent into a new era of focusing on protecting public health, returning to growth and paying down the company's debt GAITHERSBURG, Md., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS), a global company providing solutions that address public health threats and delivering life-extending products to market, today announced that its Board of Directors has appointed Joseph C. Papa as president and CEO, effective February 21, 2024. Mr. Papa succeeds Haywood Miller, who will step down from his role as interim CEO, effective February 21, 2024. "Following a thorough search process, we are pleased to appoint Joe Papa as president and CEO of Emergent," sai
SC 13G - Bausch & Lomb Corp (0001860742) (Subject)
Delivered meaningful EBITDA margin expansion and operating leverage in the fourth quarter Fourth-Quarter 2025 Financial Results Revenue of $1.405 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $58 Million Adjusted EBITDA (non-GAAP)1 of $326 Million; Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP)1 of $330 Million Revenue Grew 10% as Reported and 7% on a Constant Currency1 Basis Compared to the Fourth Quarter of 2024 Full-Year 2025 Financial Results Revenue of $5.101 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $360 Million Adjusted EBITDA (non-GAAP)1 of $858 Million; Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP)1
Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its fourth-quarter and full-year 2025 financial results on Wednesday, Feb. 18, 2026. The company will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call. Conference Call Details Date: Wednesday, Feb. 18, 2026 Time: 8:00 a.m. ET Webcast: https://www.webcaster5.com/Webcast/Page/2883/53392 Pa
Revenue of $1.281 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $28 Million Adjusted EBITDA (non-GAAP)1 of $243 Million; Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP)1 of $243 Million Revenue Grew 7% as Reported and 6% on a Constant Currency1 Basis Compared to the Third Quarter of 2024 Updating Full-Year 2025 Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP)1 Guidance Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its third-quarter 2025 financial results. "We're delivering on the vision we laid out in 2023, with a base business engine that con